These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21208841)

  • 41. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
    Davis LE
    Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical biomarkers in colorectal cancer.
    Morris V; Kopetz S
    Clin Adv Hematol Oncol; 2013 Dec; 11(12):768-76. PubMed ID: 24893280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives.
    Nappi A; Berretta M; Romano C; Tafuto S; Cassata A; Casaretti R; Silvestro L; Divitiis C; Alessandrini L; Fiorica F; Ottaiano A; Nasti G
    Curr Cancer Drug Targets; 2018; 18(5):421-429. PubMed ID: 28183254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update on the current and emerging targeted agents in metastatic colorectal cancer.
    Chu E
    Clin Colorectal Cancer; 2012 Mar; 11(1):1-13. PubMed ID: 21752724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor endothelial markers as a target in cancer.
    Ribatti D; Ranieri G; Basile A; Azzariti A; Paradiso A; Vacca A
    Expert Opin Ther Targets; 2012 Dec; 16(12):1215-25. PubMed ID: 22978444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating many treatments and biomarkers in oncology: a new design.
    Kaplan R; Maughan T; Crook A; Fisher D; Wilson R; Brown L; Parmar M
    J Clin Oncol; 2013 Dec; 31(36):4562-8. PubMed ID: 24248692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Molecular biomarkers to predict outcome in colorectal cancer- current evidence and future perspectives].
    Taniguchi H
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1367-71. PubMed ID: 25577804
    [No Abstract]   [Full Text] [Related]  

  • 48. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation.
    Weinberg BA; Hartley ML; Salem ME
    Oncology (Williston Park); 2017 Jul; 31(7):573-80. PubMed ID: 28712102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required.
    Eng C; Rogers JE
    Expert Opin Pharmacother; 2019 Apr; 20(5):523-534. PubMed ID: 30590946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Promising molecular targeted therapies in breast cancer.
    Munagala R; Aqil F; Gupta RC
    Indian J Pharmacol; 2011 May; 43(3):236-45. PubMed ID: 21713084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.
    Troiani T; Martinelli E; Napolitano S; Morgillo F; Belli G; Cioffi L; Ciardiello F
    Curr Med Chem; 2014; 21(14):1639-53. PubMed ID: 23992332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinically relevant cancer biomarkers and pharmacogenetic assays.
    Patel JN; Mandock K; McLeod HL
    J Oncol Pharm Pract; 2014 Feb; 20(1):65-72. PubMed ID: 23353710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives.
    Personeni N; Smiroldo V; Giunta EF; Prete MG; Rimassa L; Bregni G; Sclafani F
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients.
    Riera P; Rodríguez-Santiago B; Lasa A; Gonzalez-Quereda L; Martín B; Salazar J; Sebio A; Virgili AC; Minguillón J; Camps C; Surrallés J; Páez D
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DxS Ltd.
    Cross J
    Pharmacogenomics; 2008 Apr; 9(4):463-7. PubMed ID: 18384259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colorectal cancer stem cells as biomarkers: where it all starts?
    Avital I; Summers TA; Steele SR; Waldman S; Nissan A; Bilchik AJ; Protic M; Man YG; Brücher BL; Stojadinovic A
    J Surg Oncol; 2013 Jun; 107(8):791-3. PubMed ID: 23512573
    [No Abstract]   [Full Text] [Related]  

  • 57. Metastatic Colorectal Cancer: Prognostic and Predictive Factors.
    Nappi A; Nasti G; Romano C; Berretta M; Ottaiano A
    Curr Med Chem; 2020; 27(17):2779-2791. PubMed ID: 31218949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline.
    Yu IS; Aubin F; Goodwin R; Loree JM; Mather C; Sheffield BS; Snow S; Gill S
    Ther Adv Med Oncol; 2022; 14():17588359221111705. PubMed ID: 35898967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream.
    Goel G
    Cancer Manag Res; 2018; 10():5895-5908. PubMed ID: 30510457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review.
    Ruiz-Bañobre J; Kandimalla R; Goel A
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.